LMAT (69) XRAY (32) UFPT (77) KMTS (50) ⌘ Pro Terminal →

Inspire Medical Systems Inc. (INSP) — RQD Stock Rating Cockpit

$71.18 +0.30% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $71.08

Inspire Medical Systems Inc. (INSP) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 66/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.4% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $2.06B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INSP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Inspire Medical Systems Inc. (NYSE: INSP) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $71.18 (+0.30% 1D, market cap $2.06B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, INSP ranks #119 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INSP compare to LMAT and XRAY in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), INSP carries a Roarable C+ (66/100 RQD), trailing P/E of 14.2x, gross margin of 85.4%, and ROIC of 6.0%. By comparison, LMAT (LeMaitre Vascular Inc.) holds a C+ grade (69/100 RQD, P/E 33.8x, ROIC 14.7%, cap $1.95B) and XRAY (DENTSPLY SIRONA Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.92B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INSP?

▼

Per INSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001609550), Inspire Medical Systems Inc. generated $912.0M in revenue (+13.6% YoY), $145.4M in net income, and $78.5M in free cash flow against $907.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $71.08 (-0.14%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 8.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 66/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.4% avg 90D alpha vs SPY • 56.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INSP)Realized 20D OHLCV Swing Band: ±7.6%

Deterministic 5-Pillar Attribution (66/100 Composite)

🔍 WHY INSP SCORES 66/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (27% of score)

Altman Z-Score 11.40 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)

▼ #1 Drag / Risk Factor: Cash Engine Quality8/20 pts (-12 pt drag)

Capital intensity & 5.6% operating margin leave 12 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$71.49-1.9% Next Q

Q2 (-2Q)

Grade B$70.15+1.2% Next Q

Q3 (-1Q)

Grade B-$71.01+0.2% Next Q

Current

Grade C+$71.18+1.4% Hist 90D α

Trajectory: B+ (74) → C+ (66)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INSP Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 66/100 (C+) score, INSP faces multiple-compression risk if 14.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 82.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($68.77) or 200D SMA ($58.45) invalidates the momentum regime and cuts Target Base ($73.74) toward Bear Floor ($57.52).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INSP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INSP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 66%NO 34%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

53.530 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

11.40>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE30% OF RANGE

L: $39$71.18H: $147

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C+RQD 27 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B+RQD 31 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on INSP

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

6.0% ROIC with 85.4% gross margin and 3.81% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (90)

Altman-Z 11.40 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (67)

27/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like INSP

✓Company leadership has skin in the game with net positive insider conviction.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (INSP Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INSP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.80%🛡️ HOLDING TREND SUPPORT

2026-11-02O $70.97H $71.18L $70.97C $71.18VOL 512.6K

RES: $91.00SUP: $70.39SMA50: $68.77SMA200: $58.45

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INSP Butterfly Map → + Track INSP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

6.0%/yr Implied 5Y Growth

vs. +13.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INSP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INSP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INSP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INSP)

Health Care Rank #119 of 1016 ⚔️ LMAT vs INSP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INSP vs. LMAT, XRAY, UFPT, KMTS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Inspire Medical Systems Inc. (INSP) ranks #119 by composite RQD confidence (66/100, grade C+) and #256 by equity capitalization ($2.06B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. UFPT currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with INSP at 66/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INSP ACTIVE Inspire Medical Systems Inc.	C+	66/100	14.2x	85.4%	6.0%	+0.30%	$2.06B	Benchmark Subject
LMAT LeMaitre Vascular Inc.	C+	69/100	33.8x	71.5%	14.7%	+2.90%	$1.95B	/lmat-vs-insp →
XRAY DENTSPLY SIRONA Inc.	E	32/100	—	50.0%	-11.0%	+1.80%	$1.92B	/xray-vs-insp →
UFPT UFP Technologies Inc.	B+	77/100	33.3x	28.3%	13.9%	+2.55%	$2.27B	/ufpt-vs-insp →
KMTS Kestra Medical Technologies Ltd.	D	50/100	—	51.4%	-35.0%	+2.48%	$1.82B	/kmts-vs-insp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001609550

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Inspire Medical Systems Inc. (INSP) reported GAAP revenue of $912.0M (+13.6% vs. FY2024 revenue of $802.8M , and +46.0% cumulative change since FY2023) , GAAP net income of $145.4M, operating cash flow of $117.0M, and free cash flow of $78.5M (-13.9% YoY). On the balance sheet, INSP closed FY2025 with $907.3M in total assets against $0 in total debt (Altman Z-Score: 11.40, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$912.0M	$145.4M	$117.0M	$78.5M	$907.3M	—
FY2024 (FY)	2024-12-31	$802.8M	$53.5M	$130.2M	$91.1M	$808.4M	—
FY2023 (FY)	2023-12-31	$624.8M	-$21.2M	$24.7M	$24.7M	—	—

3. INSP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INSP compare to LMAT and XRAY in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INSP?

Where is INSP trading relative to its 50-day, 200-day, and 52-week technical levels?

INSP last traded at $71.18 (+0.30% on volume of 512,603 shares), positioning the stock +3.50% above its 50-day simple moving average ($68.77) and +21.78% above its 200-day simple moving average ($58.45). Across its 52-week range of $38.91 to $147.03, INSP sits at the 29.8% percentile with a 14-day RSI of 53.5 (NEUTRAL RANGE) and an implied next-earnings move of ±7.6% ($65.77 to $76.59).

INSP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell INSP stock right now?

Inspire Medical Systems Inc. (INSP) currently earns a Roarable Rating of C+ (Hold — HOLD) with 66/100 RQD Confidence. Solid 85% profit margin (6% return on capital), mixed timing at 14x P/E—hold if owned, no rush to chase.

What is INSP's 12-month price target and RQD AI Jury consensus?

INSP's 12-month base price target is $73.74 (range $57.52 to $154.38), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: INSP RQD Cockpit INSP 12M Forecast INSP Earnings & Move INSP Dividends & DRIP INSP Insiders & 13F INSP Whale Options INSP Profit Sankey INSP News & Why